Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Position Raised by Kestra Investment Management LLC

Kestra Investment Management LLC boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 104.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,260 shares of the biopharmaceutical company's stock after buying an additional 644 shares during the quarter. Kestra Investment Management LLC's holdings in Regeneron Pharmaceuticals were worth $898,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the company. Nvwm LLC grew its position in shares of Regeneron Pharmaceuticals by 1.4% in the third quarter. Nvwm LLC now owns 988 shares of the biopharmaceutical company's stock valued at $1,039,000 after purchasing an additional 14 shares during the last quarter. Westhampton Capital LLC raised its stake in shares of Regeneron Pharmaceuticals by 1.7% during the third quarter. Westhampton Capital LLC now owns 893 shares of the biopharmaceutical company's stock valued at $939,000 after purchasing an additional 15 shares during the period. Howe & Rusling Inc. boosted its stake in Regeneron Pharmaceuticals by 3.4% during the 3rd quarter. Howe & Rusling Inc. now owns 462 shares of the biopharmaceutical company's stock valued at $486,000 after acquiring an additional 15 shares during the last quarter. Willner & Heller LLC increased its holdings in Regeneron Pharmaceuticals by 3.9% in the fourth quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company's stock valued at $284,000 after buying an additional 15 shares during the last quarter. Finally, OLD Second National Bank of Aurora raised its stake in Regeneron Pharmaceuticals by 0.5% during the fourth quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company's stock worth $2,025,000 after acquiring an additional 15 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. Robert W. Baird dropped their price target on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating on the stock in a research report on Wednesday, February 5th. Leerink Partnrs raised Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 5th. Wolfe Research began coverage on shares of Regeneron Pharmaceuticals in a report on Friday, November 15th. They issued an "outperform" rating and a $1,150.00 price target for the company. UBS Group lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and cut their target price for the stock from $1,130.00 to $738.00 in a report on Thursday, January 16th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an "overweight" rating on the stock in a report on Thursday, October 24th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $973.13.

Regeneron Pharmaceuticals Stock Performance

REGN traded up $4.31 on Friday, reaching $700.33. 727,332 shares of the stock were exchanged, compared to its average volume of 923,518. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $642.00 and a fifty-two week high of $1,211.20. The company's 50-day moving average price is $700.02 and its 200 day moving average price is $886.33. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The firm has a market capitalization of $76.56 billion, a PE ratio of 18.29, a PEG ratio of 2.30 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same period in the prior year, the company earned $11.86 earnings per share. The firm's revenue was up 10.3% on a year-over-year basis. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.50%. The ex-dividend date is Thursday, February 20th.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.